INSUBCONTINENT EXCLUSIVE:
Enoxaparin Salt injection is likewise utilized for the treatment of severe deep vein thrombosisZydus Pharmaceuticals, U.S.A., signed a
license and supply arrangement with Italy's CHEMI MEDICAL SPA or CHEMI - a subsidiary of Italfarmaco Group, to introduce the Enoxaparin
Sodium injection in the United States (United States)
The injection is normally given to clients undergoing stomach, knee or hip replacement surgery
The item is a generic equivalent of Sanofi Aventis's branded product Lovenox, according to a regulatory filing by Cadila Health care to the
Zydus Pharma Inc, USA is an one hundred percent subsidiary of Cadila Healthcare Limited or Zydus Cadila.As part of the contract, CHEMI will
manufacture and provide the Enoxaparin Salt injection which Zydus Cadila will advertise in the United States
Utilising their proprietary technology, CHEMI will produce the Enoxaparin Sodium injection within the exclusive manufacturing centers
positioned in Italy.The leading specialty pharmaceutical company owns the exclusive rights on a pharmaceutical product made up of
preservative-free Enoxaparin Salt single-use pre-filled syringes, according to the statement.The Enoxaparin Salt injection is used for the
treatment of deep vein apoplexy or DVT in patients going through stomach, hip, or knee replacement surgery
The injection is also offered for the treatment of acute DVT
Enoxaparin serves as a blood thinner by producing an antithrombotic result, added Cadila Healthcare in its declaration
The injection had annual sales of around $513 million in the United States, according to IQVIA information as of June 2021
On Friday, August 20, shares of Cadila Healthcare were last trading 1.43 per cent lower at Rs 534.95 on the BSE
Cadila Healthcare opened on the BSE at Rs 540, inching to an intra day high of Rs 547.85 and an intra day low of Rs 522, in the session up
